The GMP release of its first DS facility in China enhances WuXi Vaccines' capability in providing global partners with comprehensive end-to-end solutions, and demonstrates the company's continued commitment to meeting increased demand for vaccine development and manufacture, as well as expanding vaccine accessibility around the world. 

The DS facility employs the proven and reliable CHO cell-culture platform, and utilizes single-use bioreactors up to 1000L – a combination that enhances both the efficiency and quality of drug substance production. To further cater to the diverse needs of global partners, the Suzhou site is also expanding manufacturing capability by developing its DS capacity based on microbial and viral platforms up to BSL2, and building a fill & finish facility that will offer liquid, lyophilization, suspension and emulsion processes. Dedicated to maintaining the highest levels of quality and safety, the Suzhou site upholds stringent global cGMP standards and complies with the regulatory guidelines of the U.S. FDA, EU EMA, China NMPA, and WHO.

Mr. Jian Dong, CEO of WuXi Vaccines, commented, "The release of the drug substance facility at our Suzhou site and the start of manufacturing marks a major milestone for WuXi Vaccines. Leveraging our expertise, advanced facilities, and innovative technology platforms, while adhering to global cGMP standards and regulatory guidelines, we are primed to meet the rising demand for vaccine development and manufacture, and advance the availability of safe and effective vaccines worldwide."